Jump to content

Ziyad Al-Aly

Add links
From Wikipedia, the free encyclopedia

Ziyad Al-Aly is an American physician and clinical epidemiologist who is currently Director of the Clinical Epidemiology Center and Chief of the Research and Development at the Veterans Affairs St. Louis Health Care System.[1][2][3] He is also a clinical epidemiologist at Washington University in St. Louis.[2] He has led multiple studies on long covid and its sequelae.[4]

Early life

[edit]

Al-Aly was born in Tripoli, Lebanon to teachers.[5] He grew up during the Lebanese civil war which dominated Lebanon from 1975 to 1990,[5] emigrating to the United States in 2000.

Education

[edit]

Al-Aly holds a medical degree from the American University of Beirut.[6] He completed his post-graduate medical education at Saint Louis University and Washington University in St. Louis.

Career

[edit]

Al-Aly's research work has been cited more than a 140,000 times and he has an h-index of more than 90 according to Google Scholar.[7] Al-Aly was featured on Clarivate (Web of Science) list of highly cited researchers in 2024; the list recognizes researchers with significant influence, top 1% cited papers, and broad community recognition.

Long COVID research

[edit]

Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection.[8] He subsequently led work which characterized the increased risks of cardiovascular disease,[9] neurologic disorders,[10] mental health disorders,[11] gastrointestinal disorders,[12] diabetes,[13] dyslipidemia,[14] and kidney disease[15] following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of COVID-19 vaccines on long COVID[16] and the health consequences of repeated infections with SARS-CoV-2.[17]

In 2024, Al-Aly testified before the U.S. Senate Health, Education, Labor and Pensions Committee as an expert witness on Long Covid. He called for the establishment of an NIH institute to address Long Covid and Infection-Associated Chronic Conditions and Illnesses (IACCIs) — also called post-acute infection syndromes — with a funding of at least $1 billion per year.[18][19]

Pharmacoepidemiology

[edit]

Including work characterizing the adverse health effect of proton pump inhibitors and comparative effectiveness of antihyperglycemic medications. His work also included examining the effectiveness of COVID-19 antivirals including paxlovid (nirmatrelvir/ritonavir) and molnupiravir on acute COVID-19 outcomes[20][21] and long COVID.[22][23]

Environmental epidemiology research

[edit]

Including work which evaluated the effect of air pollution on kidney health,[24] diabetes,[25] obesity,[26] and early mortality.[27]

Honors and awards

[edit]

In 2023, Al-Aly was awarded the U.S. Department of Veterans Affairs Secretary's Award — the highest VA award — for outstanding contributions to research. He was named one of the 100 most influential people in health in 2024 by TIME100 Health. Al-Aly was recognized with the HealthCentral’s 2024 Chronic Health Innovator Award for his research and advocacy that led to the recognition of Long Covid as a chronic disease. He was listed on the 2024 Fierce 50 — an annual list that recognizes people driving major advancements in medicine and shaping the future of healthcare. 

References

[edit]
  1. ^ "Repeat coronavirus infections can still be dangerous, study suggests". The Washington Post. Retrieved 11 November 2022.
  2. ^ a b "Ziyad Al-Aly, MD". Washington University in St. Louis. Retrieved 11 November 2022.
  3. ^ Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-03.
  4. ^ "COVID-19 infections increase risk of long-term brain problems". Washington University in St. Louis. 22 September 2022. Retrieved 11 November 2022.
  5. ^ a b Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-05.
  6. ^ "Ziyad Al-Aly, MD, FASN". Washington University in St. Louis. Retrieved 11 November 2022.
  7. ^ "Ziyad Al-Aly, MD". Google Scholar. Retrieved 11 January 2024.
  8. ^ Al-Aly, Ziyad; Xie, Yan; Bowe, Benjamin (June 2021). "High-dimensional characterization of post-acute sequelae of COVID-19". Nature. 594 (7862): 259–264. Bibcode:2021Natur.594..259A. doi:10.1038/s41586-021-03553-9. ISSN 1476-4687. PMID 33887749. S2CID 233373053.
  9. ^ Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad (March 2022). "Long-term cardiovascular outcomes of COVID-19". Nature Medicine. 28 (3): 583–590. doi:10.1038/s41591-022-01689-3. ISSN 1546-170X. PMC 8938267. PMID 35132265.
  10. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (November 2022). "Long-term neurologic outcomes of COVID-19". Nature Medicine. 28 (11): 2406–2415. doi:10.1038/s41591-022-02001-z. ISSN 1546-170X. PMC 9671811. PMID 36138154.
  11. ^ Xie, Yan; Xu, Evan; Al-Aly, Ziyad (2022-02-16). "Risks of mental health outcomes in people with covid-19: cohort study". BMJ. 376: e068993. doi:10.1136/bmj-2021-068993. ISSN 1756-1833. PMC 8847881. PMID 35172971.
  12. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-03-07). "Long-term gastrointestinal outcomes of COVID-19". Nature Communications. 14 (1): 983. Bibcode:2023NatCo..14..983X. doi:10.1038/s41467-023-36223-7. ISSN 2041-1723. PMC 9992516. PMID 36882400.
  13. ^ Xie, Yan; Al-Aly, Ziyad (2022-05-01). "Risks and burdens of incident diabetes in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 10 (5): 311–321. doi:10.1016/S2213-8587(22)00044-4. ISSN 2213-8587. PMC 8937253. PMID 35325624.
  14. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-02-01). "Risks and burdens of incident dyslipidaemia in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 11 (2): 120–128. doi:10.1016/S2213-8587(22)00355-2. ISSN 2213-8587. PMC 9873268. PMID 36623520.
  15. ^ Bowe, Benjamin; Xie, Yan; Xu, Evan; Al-Aly, Ziyad (November 2021). "Kidney Outcomes in Long COVID". Journal of the American Society of Nephrology. 32 (11): 2851–2862. doi:10.1681/ASN.2021060734. ISSN 1046-6673. PMC 8806085. PMID 34470828. S2CID 237389462.
  16. ^ Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan (July 2022). "Long COVID after breakthrough SARS-CoV-2 infection". Nature Medicine. 28 (7): 1461–1467. doi:10.1038/s41591-022-01840-0. ISSN 1546-170X. PMC 9307472. PMID 35614233.
  17. ^ Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad (November 2022). "Acute and postacute sequelae associated with SARS-CoV-2 reinfection". Nature Medicine. 28 (11): 2398–2405. doi:10.1038/s41591-022-02051-3. ISSN 1546-170X. PMC 9671810. PMID 36357676.
  18. ^ "Testimony of Ziyad Al-Aly, M.D., Clinical Epidemiologist, Washington University in Saint Louis, Saint Louis, MO Before United States Senate Committee on Health, Education, Labor and Pensions" (PDF). U.S. Senate Committee on Health, Education, Labor and Pensions. January 18, 2024. Archived from the original (PDF) on 2024-01-18.
  19. ^ Al-Aly, Ziyad; Davis, Hannah; McCorkell, Lisa; Soares, Letícia; Wulf-Hanson, Sarah; Iwasaki, Akiko; Topol, Eric J. (August 2024). "Long COVID science, research and policy". Nature Medicine. 30 (8): 2148–2164. doi:10.1038/s41591-024-03173-6. ISSN 1546-170X. PMID 39122965.
  20. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-04-11). "Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 381: e073312. doi:10.1136/bmj-2022-073312. ISSN 1756-1833. PMC 10086514. PMID 37041016.
  21. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-03-07). "Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 380: e072705. doi:10.1136/bmj-2022-072705. ISSN 1756-1833. PMC 9989554. PMID 36882199.
  22. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-06-01). "Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition". JAMA Internal Medicine. 183 (6): 554–564. doi:10.1001/jamainternmed.2023.0743. ISSN 2168-6106. PMC 10037200. PMID 36951829.
  23. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-04-25). "Molnupiravir and risk of post-acute sequelae of covid-19: cohort study". BMJ. 381: e074572. doi:10.1136/bmj-2022-074572. ISSN 1756-1833. PMC 10126525. PMID 37161995.
  24. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (January 2018). "Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD". Journal of the American Society of Nephrology. 29 (1): 218–230. doi:10.1681/ASN.2017030253. ISSN 1046-6673. PMC 5748906. PMID 28935655.
  25. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (July 2018). "The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution". The Lancet Planetary Health. 2 (7): e301–e312. doi:10.1016/s2542-5196(18)30140-2. ISSN 2542-5196. PMID 30074893.
  26. ^ Bowe, Benjamin; Gibson, Andrew K.; Xie, Yan; Yan, Yan; Donkelaar, Aaron van; Martin, Randall V.; Al-Aly, Ziyad (April 2021). "Ambient Fine Particulate Matter Air Pollution and Risk of Weight Gain and Obesity in United States Veterans: An Observational Cohort Study". Environmental Health Perspectives. 129 (4). doi:10.1289/EHP7944. ISSN 0091-6765. PMC 8016176. PMID 33793302.
  27. ^ Bowe, Benjamin; Xie, Yan; Yan, Yan; Al-Aly, Ziyad (2019-11-20). "Burden of Cause-Specific Mortality Associated With PM 2.5 Air Pollution in the United States". JAMA Network Open. 2 (11): e1915834. doi:10.1001/jamanetworkopen.2019.15834. ISSN 2574-3805. PMC 6902821. PMID 31747037.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ziyad_Al-Aly&oldid=1260146824"